Graft-versus-host disease (GVHD) is the most common complication after hematopoietic stem cell transplantation. To clarify the role of Toll-like receptor 4 (TLR4), which is a major receptor for bacterial lipopolysaccharides (LPS), in the development of acute GVHD, we used a TLR4-knockout (TLR4 2/2 ) mouse GVHD model and analyzed the underlying immunological mechanisms. When TLR4 2/2 mice were used as bone marrow and splenocyte cell graft donors or recipients, GVHD symptom occurrence and mortality were delayed compared to wild-type (TLR4 1/1 ) mice. In addition, histopathological analyses revealed that in TLR4 2/2 RBALB/c chimeras, liver and small intestine tissue damage was reduced with minimal lymphocytic infiltration. In contrast to TLR4 1/1 , TLR4 2/2 mice dendritic cells did not express CD80, CD86, CD40, MHC-II or IL-12 during LPS induction and remained in an immature state. Furthermore, the ability of TLR4 2/2 mice spleen dendritic cells to promote allogeneic T-cell proliferation and, in particular, T-helper cell 1 (Th1) development was obviously attenuated compared with TLR4 1/1 mice dendritic cells, and the levels of interferon-c (IFN-c) and IL-10, Th2-cell specific cytokines, were significantly higher in the serum of TLR4 2/2 RBALB/c than in TLR4 1/1 RBALB/c chimeric mice. Overall, our data revealed that TLR4 may play a role in the pathogenesis of GVHD and that targeted TLR4 gene therapy might provide a new treatment approach to reduce the risk of GVHD.
INTRODUCTION
Hematopoietic stem cell transplantation (HSCT) has become one of the main strategies for the treatment of malignant hematological diseases. Unfortunately, the benefit of this treatment is limited by a number of serious side effects, including graftversus-host disease (GVHD). The complex and intricate pathophysiology of acute GVHD is a consequence of interactions between the donor and host innate and adaptive immune responses. 1 Activation of donor T cells by antigen-presenting cells (APCs) is the most important among the three stages described in acute GVHD, as the activated T cells migrate to target organs and cause damage in the recipient target tissue. 2 It has been reported that both host-derived and donor-derived APCs are present in secondary recipient lymphoid tissues after allogeneic bone marrow transplantation (BMT). T-cell receptors of the donor T cells can recognize alloantigens on the host APCs (direct presentation) as well as donor APCs (indirect presentation). [2] [3] [4] Recent studies suggest that sufficient CD86, CD80 and CD40 costimulatory molecule expression of the APCs determine whether T cells are fully activated, and an immune response is triggered and inactivation leads to apoptosis or disability in T-cell early responses. It has been reported that dendritic cells (DCs) are a type of APC that have the strongest antigen-presenting ability and can uniquely activate naive T cells, leading to acute graft rejection. 1, 5 DCs in an immature state demonstrate significantly less antigenpresenting ability, and reduced DCs in a mixed allogeneic Tcell lymphocyte reaction lead to weak T-cell proliferation with a reduced occurrence of GVHD. In addition to human leukocyte antigen mismatching between donors and recipients being the main reason of GVHD, bacterial infections are also an important inducing factor. 6 After radio-and chemotherapy cause damage of the intestinal mucosa in recipients, bacteria can pass into the blood via the damaged tissue. The endotoxin receptor Toll-like receptor 4 (TLR4) can recognize endotoxin lipopolysaccharides (LPS) as a pathogen-associated molecular pattern in Gram-negative bacterial cell walls. TLR4 then induces the nuclear factor-kappaB signal pathway, 7 leading to the expression of the costimulatory molecules necessary for the activation and differentiation of T lymphocytes, 8 including the release of inflammatory factors, such as TNF-a, IL-1, IL-6, NO and other cytokines, finally activating the acquired immune system with concomitant triggering of GVHD. 9 Data obtained from mouse GVHD models have shown that disruption of cellular LPS activation effects can significantly reduce GVHD severity. 10 As TLR4 has been shown to be a key player in innate immunity and immune tolerance, 11, 12 TLR4 gene defects have been suggested to alter the function of the receptor, thereby leading to reduced proinflammatory cytokine responses and increased susceptibility to Gram-negative infections. 13 Several researchers who focused on TLR4 gene alterations and effects on immune response have found that the distribution of TLR4 gene polymorphisms in Caucasians and Asians is different. Raby and his collaborator reported that TLR4 polymorphisms within the North American cohort/Native American groups in the United States varies with a gene mutation rate of 0.8%-10%. 14 Other studies have shown the incidence of being a TLR4 Asp299Gly and Thr399Ile carrier (including homozygotes and heterozygotes) worldwide lies in the range of 2.5%-20.7%. [15] [16] [17] [18] [19] The TLR4 Asp299Gly polymorphism, in particular, is the highest in African Americans, while in a western Iran population, the highest incidence for a mutation was found for the TLR4 Thr399Ile polymorphism, which is in, contrast, very rare in Asian populations, such as those in Japan and South Korea. 20, 21 Carriers of the Thr399Ile TLR4 gene mutation have a significantly increased risk of developing GVHD, 42% versus 15% of non-affected patients, whereas transplant-related mortality, overall survival rate and the incidence of infectious complications are not influenced by the mutated gene. 22 Histopathological changes in the small intestine are more severe in TLR4-mutant host GVHD recipients than those in TLR4-intact host GVHD recipients at 14 days after GVHD development, 23 but the studies reporting these results did not clearly demonstrate the role of TLR4 in the HSCT-related pathogenesis of GVHD. One retrospective study indicated that TLR4 mutations reduced the risk of acute GVHD in humans, 24 but other studies have noted that there was no significant influence of TLR4 on the incidence of GVHD. 25, 26 To elucidate the role of TLR4 in acute GVHD, we used TLR4-knockout mice (TLR4 2/2 ) in myeloablative bone marrow and splenocyte cell donor or recipient models and observed the morphology and GVHD extent of the recipient mice after HSCT. We further analyzed the CD80, CD86, CD40 and MHC-II expression levels of (TLR4 ) DC and allogeneic T-cell mixed lymphocyte reaction (MLR). Based on our results, we suggest that TLR4 inhibition might protect against GVHD in recipients after allogeneic HSCT. Reagents RPMI 1640 medium and fetal bovine serum were obtained from PAA Laboratories (Linz, Austria). Recombinant mouse granulocyte-monocyte colony stimulating factor, IL-4 and enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems (Minneapolis, MN, USA). Fluorescein-conjugated murine antibodies were purchased from BD Pharmingen (San Diego, CA, USA) and eBioscience (San Diego, CA, USA). Microbead-conjugated murine antibodies against CD3, CD4, CD19 and CD11c were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). 7-Aminoactinomycin D (7-AAD), saponin, indomethacin, brefeldin A, bovine serum albumin, 1-methyltryptophan and carboxyfluorescein diacetate succinimidyl ester (CFSE) were purchased from Sigma (St Louis, MO, USA). Lipopolysaccharide (ultrapure Escherichia coli 0111:B4) was obtained from InvivoGen (San Diego, CA, USA).
MATERIALS AND METHODS

Induction of GVHD
Myeloablation of TLR4
1/1 and TLR4 2/2 mice was performed by whole-body irradiation, with a total dose of 1050 cGy ( 60 Co source) given twice with a 3-h interval to minimize gastrointestinal toxicity. This was followed by an injection of BALB/c donor-derived bone marrow and splenocyte cells into the caudal tail veins. Reverse experiments were performed by using irradiated BALB/c mice (900 cGy ( 60 Co source), two doses with a 3-h interval) as recipients and TLR4 1/1 or TLR4 2/2 mice as donors. Bone marrow and splenocyte cell suspensions were prepared as previously described. 25 All mice received an oral suspension of gentamicin (320 mg/l) with their drinking water from 7 days before transplantation until 4 weeks after BMT.
Assessment of GVHD GVHD severity was assessed using a previously described clinical scoring system. 28 Each BMT recipient mouse was scored twice weekly for 60 days after transplantation. Weight loss, posture (hunching), activity, fur texture and skin integrity were measured using a scale from 0 to 2, with 0 for absent or normal, 1 for mild abnormal and 2 for severely abnormal. The GVHD clinical index was determined as the sum of the individual criteria scores divided by 10.
Histology
Tissue samples from the small intestines and livers of recipient mice were collected after allogeneic transplantation, and the tissue sections were examined for evidence of GVHD by established protocols. 29, 30 Cell apoptosis of the small intestine tissue was examined with the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) method, and the nuclei were stained with 49,6-diamidino-2-phenylindole (DAPI).
Preparation of DCs from mouse bone marrow
Mouse bone marrow-derived DCs were generated by established protocols. [31] [32] [33] [34] [35] On day 5, the proliferating DC clusters were collected and purified by anti-CD11c magnetic microbeads as immature DCs. Purified immature DCs were stimulated with LPS (1 mg/ml) for 24 h.
Flow cytometric analyses
Detection of cell surface marker, intracellular cytokines and quantification of proliferating T cells was performed using flow cytometry. [31] [32] [33] [34] [35] In all experiments, the cells were analyzed using FACSCalibur and LSR II flow cytometers (BD Biosciences, San Jose, CA, USA).
Western blot analysis TLR4
1/1 -and TLR4 2/2 -derived DCs were stimulated with 1 mg/ml LPS for the indicated times, harvested, lysed and then analyzed by western blots as described previously. 31 
MLR cultures
Responder cells were prepared from BALB/c mouse splenocytes, and DC stimulator cells were obtained either from TLR4
1/1 or TLR4 2/2 mice and used at the fifth day after extraction. Cytokine production in the culture supernatants or in serum was detected using ELISA kits. For intracellular cytokine staining, splenocytes were harvested 7 days after transplantation. The protocols were performed as mentioned above. [31] [32] [33] [34] Responder cells were prepared from BALB/c mouse splenocytes by negative selection with mouse CD19 microbeads (Miltenyi Biotec) to remove proliferating B cells and to accumulate T cells. Stimulator cells were obtained by positive selection with mouse MHC class II microbeads (Miltenyi Biotec) from spleen cells of C57BL/6 or TLR4-knockout mice not irradiated or lethally irradiated 24 h before the procedure. In experiments using non-irradiated mice, stimulator cells were irradiated (3000 cGy) before coculture. In experiments, which were performed for the evaluation of the TLR4/ APC capability to respond to maturation stimuli, LPS (1 mg/ml) and/or TNF-a (10 ng/ml) were added to the stimulator cell medium 24 h before coculture. In all experiments, the proliferation of responder cells was evaluated in the presence of stimulator cells obtained from three different mice per group. Proliferation of T cells was evaluated with the CellTrace CFSE Cell Proliferation Kit (Invitrogen), according to the manufacturer's instructions.
Statistical analysis
The two-tailed unpaired Student's t-test was applied for group comparisons of discrete variables. The log-rank test was used to analyze survival curves. A value of P,0.05 was considered a statistically significant difference.
RESULTS
Reduced acute GVHD severity after TLR4
2/2 mouse donorderived bone marrow and splenocyte cell transplantation into irradiated BALB/c mice BALB/c recipient mice (15/group) were myeloablative-irradiated and received 1310 7 bone marrow and 2310 7 splenocyte cells obtained from the TLR4 2/2 or TLR4 1/1 donor mice. Three mice from each recipient group were selected randomly as control mice and received a phosphate-buffered saline injection. All recipient mice were monitored for survival rate, weight changes and clinical signs of GVHD. The control mice all died of bone marrow failure within 5-10 days post-transplantation with a white blood cell count less than 0.5310 9 /l. We sampled eye blood from both groups of the recipient BALB/c (H-2k recipient mice displayed a slightly higher survival rate, with one of twelve mice still alive at the end of the experiment (day 60), but all TLR4 1/1 recipient mice died within 32 days. However, the difference in survival rates between the two groups was not significant (Figure 2b ).
TLR4
2/2 bone marrow and splenocyte cell transplantation into irradiated BALB/c recipient mice caused fewer pathohistological changes of the liver and intestine than transplantation of TLR4 1/1 donor cells Histological analyses were performed on livers (Figure 3a 1/1 cell-transplanted mice livers presented with more obvious and diffuse bleeding blots (Figure 3a ) that were heavily infiltrated with lymphocytes in the portal area and displayed endothelialitis of a hepatic vein as well as a disordered histological architecture (Figure 3c ). In contrast, no obvious bleeding spots on the surface of TLR4 2/2 celltransplanted mice livers ( Figure 3b) were visible, and minimal lymphocyte infiltration in the portal area took place with rare inflammatory cell invasion into the bile ducts (Figure 3d ). In addition, the small intestines of the TLR4 1/1 cell-transplanted mice exhibited more severe villus blunting, crypt destruction changes and greater crypt atrophy than TLR4 2/2 cell-transplanted mice. The small intestines of TLR4 1/1 mice exhibited more severe villus blunting, crypt destruction changes and crypt atrophy (e). Apoptotic crypt cells of the small intestines are shown in e (arrows, stained with H&E) and in g (arrows, stained with TUNEL) compared with TLR4 2/2 mice (f, h). Representative samples from each mouse group were processed and stained with H&E or TUNEL. Original magnification: c and d, 3200; e-h, 3400. BMT, bone marrow transplantation; H&E, hematoxylin and eosin; TLR4, Toll-like receptor 4; TUNEL, terminal deoxynucleoitidyl transferase-mediated dUTP nick end-labeling. and f depicts apoptotic crypt cells of the small intestine, stained with hematoxylin and eosin. Figure 3g and h depicts TUNEL staining.
2/2 mice-derived DCs remained immature after LPS stimulation To test the assumption that the TLR4 2/2 gene mutation might inhibit DC maturation, we stimulated TLR4 2/2 DCs with LPS and analyzed the Phospho-I kBa levels by western blotting. As visible in Figure 4a , in contrast to TLR4 mice, P,0.01) (Figure 4b and c) .
We also detected the expression of CD80 and CD86 in DCs from the spleen cells of TLR4 2/2 mice, P,0.001) ( Figure 5 ).
2/2 -derived DCs partly lost their ability to activate allogeneic T cells We analyzed the IL-12 levels in the culture medium supernatants of TLR4
1/1 and TLR4 2/2 mouse-derived DCs and found that there was no difference between them in 5-day-old DC culture medium supernatants. However, after LPS (1 mg/ml) treatment for 24 h, the level of IL-12 from TLR4
1/1 mousederived DC culture supernatants was higher than that of the culture medium supernatants of TLR4 We further studied the difference of antigen presentation and lymphocyte proliferation mediating ability between TLR4 1/1 and TLR4 2/2 mouse-derived DCs with and without LPS stimulation. CD3
1 T cells from BALB/c mice spleen were cocultured with TLR4 1/1 or TLR4 2/2 mouse-derived immature untreated and LPS-treated DCs with a responder ratio of 1 : 10 in a MLR. After 5 days, the relative number of viable T (CD3 1 7AAD 2 ) cells in each well were determined by flow cytometry, and the alloreactive BALB/c T-cell number was significantly lower in cultures stimulated by TLR4 2/2 than in cultures stimulated by TLR4
1/1 mouse-derived DCs (P,0.001) (Figure 6b ). In addition, the proliferation of BALB/c CD3 (Figure 6c ).
T cells cocultured with TLR4
2/2 mouse-derived DCs secreted fewer cytokines than T cells cocultured with TLR4
1/1 mouse-derived DCs Next, we examined cytokine secretion in media supernatants after 5 days of BALB/c T-cell coculturing with a 24-h treatment of LPS (1 mg/ml)-stimulated TLR4 2/2 and TLR4 1/1 DCs to assess the role of DCs on TLR4 2/2 on allogeneic T-cell differentiation. For the analysis, 120 ml/well culture supernatants were collected, and the levels of IFN-c, IL-2, IL-4, IL-10 and IL-17 secreted by the activated T cells in the supernatants of the MLR culture media were assayed by ELISA. The levels of IFN-c, IL-2, IL-17 in the TLR4 2/2 group decreased significantly compared to the TLR4 1/1 group (P,0.001). Interestingly, IL-10, IL-4 levels representing T-helper cell 2 (Th2) cytokines changed little in both groups (P.0.05) (Figure 6d and e).
Cytokine expression of Ths in mice 7 days after BMT To gain insight into the effect of TLR4 2/2 DCs on T-cell differentiation, we removed and ground the spleens and lymph nodes of chimeric mice 7 days after transplantation. We then incubated the mixtures in 1640 medium with phorbol myristate acetate, ionomycin and brefeldin A for 6 h. The percentage of CD4
1 T cells secreting intracellular cytokines, such as IFN-c and IL-2, was determined by FACS. The percentages of T cells secreting IFN-c and IL-2 in the TLR4 2/2 cell recipient BALB/c mice group were significantly lower than the levels observed in TLR4
1/1 -cell recipient BALB/c mice (P,0.05) (Figure 7a and  b) .
We also tested the levels of IFN-c, IL-2, IL-10 and IL-4 in the sera of recipient BALB/c mice 7 days after transplantation. To our surprise, the IFN-c levels in recipient BALB/c mice serum gradually increased after TLR4 1/1 BMT and reached its peak 7 days after transplantation, while the IFN-c levels in BALB/c mice serum that received TLR4 2/2 mice cells were significantly higher than in TLR4
1/1 mice cell recipients (P,0.05). IL-2 levels in the TLR4 2/2 mice cell recipient BALB/c mice serum were significantly lower than in TLR4
1/1 mice cell recipients (P,0.05). IL-10 levels representing Th2-related subsets of cytokines in TLR4 2/2 mice cell recipient BALB/c mice serum were significantly higher (P,0.05), while IL-4 levels were not significantly different between both groups (Figure 7c ).
DISCUSSION
To evaluate the effects of TLR4
2/2 mouse-derived DCs on GVHD with direct and indirect presentation, we designed a mouse GVHD model with TLR4
1/1 and TLR4 2/2 mice as the recipients and injected bone marrow and splenocyte cells obtained from BALB/c mice as donors. In a subsequent reversedirection experiment, we used BALB/c mice as recipients and TLR4
1/1 and TLR4 2/2 mice as donors. The transplantation rate of our chimeric mice was in accordance with a previous report, which indicated that approximately 90% of DCs in the recipient mice spleens were donor derived 14 days after transplantation. 4 Our results demonstrated that TLR4 2/2 mice, either as donors or recipients, led to chimera that developed less severe and delayed GVHD (median time: 16.1 days vs. 12.3 days), with reduced weight loss and minor liver and small intestine damage.
We need to point out that there was no significant difference in the survival curves between the TLR4 2/2 or TLR4 1/1 mice as recipient groups with otherwise significant higher BALB/c recipient mortality with TLR4 1/1 donor cells after allogeneic BMT. We consider that TLR4 2/2 mice may have been more sensitive to radiation, as we found that TLR4 2/2 mice were more prone to radiation sickness under myeloablative irradiation. Upon investigating the reduced GVHD severity after allogeneic BMT related to TLR4 knockout, we first found that even after LPS stimulation, they did not express Phospho-I kBa, in contrast to TLR4
1/1 -derived DCs, indicating that the nuclear factor-kappaB pathway was no longer functional.
Recent studies suggest that DCs express the highest level of MHC class II molecules and CD86, CD80 and CD40 on their surface, thereby playing a major role in the activation of naive T lymphocytes. In cases where the APC cannot express enough costimulatory molecules, T cells may not be completely activated, leading to anergy or apoptosis. 1, 5 Our FACS data demonstrate that day-5 DCs from TLR4 1/1 mice, after being stimulated by exogenous LPS (1 mg/ml) for 24 h, expressed high levels of CD80, CD86, CD40 and MHC-II molecules and displayed mature DC phenotypes and increased IL-12 secretion levels, while TLR4 2/2 -derived day-5 DCs still maintained immature phenotypes without costimulatory CD80, CD86, CD40, MHC-II molecule upregulation and their IL-12 secretion did not differ with or without LPS stimulation.
In an MLR experiment, we found that TLR4 2/2 -derived DCs had an attenuating effect on allogeneic T-cell activation compared to the TLR4 1/1 group. In addition, an in vivo experiment demonstrated that the expression of the costimulatory molecules CD80 and CD86 in DCs, obtained from the spleen cells of TLR4 2/2 RBALB/c mice 21 days after BMT, was significantly decreased compared to TLR4 1/1 RBALB/c. IL-12, mainly produced by dendritic cells in response to LPS, can induce IFN-c production and trigger CD4
1 T cells to differentiate into Th1 phenotypes, 36 while the proliferation of T cells is inhibited by insufficient IL-12 expression. The immature phenotype-displaying TLR4 2/2 -derived DCs significantly lost their antigen-presenting ability after LPS treatment, and reduced MLR stimulation of allogeneic T cells by these DCs led to weaker T-cell proliferation and induction.
It has been suggested that the Th1/Th2 polarization of the T helper cells plays an important role in the development of GVHD. The Th1 cell switch to Th2 can change the local graft immune response and inhibit cell-mediated rejections. 37, 38 As the cytokines produced by the Th1 subset are associated with the severity and mortality of GVHD, 39, 40 we examined the effect of TLR4 2/2 DCs on allogeneic CD4 1 T-cell differentiation in a MLR cocultivation experiment, and we analyzed the expression of Th-related cytokines in the supernatant of the MLR culture media. We concluded that the levels of cytokines produced by the Th1 subset, IFN-c and IL-2, significantly decreased in TLR4 2/2 mice DC and allogeneic CD4 1 T-cell cocultures (P,0.01), while the levels of cytokines produced by the Th2 subset, IL-10 and IL-4, also significantly decreased at the same time (P,0.05).
These results underline that DCs from TLR4 2/2 mice cannot fully activate the proliferation of Th1 subset, and there is no Th1 switch to Th2. To further investigate the relative levels of cytokines produced by the Th1/Th2 subsets after BMT in our mouse GVHD model, we used the ELISA method to quantify serum cytokines in chimeric mice 7 days post-transplantation and found that the level of the Th1 subset representing IL-2 was significantly lower than that in TLR4 2/2 donor mice. Surprisingly, the level of IFN-c was significantly higher than that of TLR4 1/1 RBALB/c mice. We suggest that other cells, such as natural killer cells and APCs, in addition to T cells, also probably secreted higher amounts of IFN-c. However, our results are consistent with other findings that IFN-c can reduce the occurrence of GVHD by negatively regulating alloreactive T cells via inhibiting cell differentiation. 41, 42 With TLR4 2/2 mice as donors, in the serum of recipient BALB/c mice on day 7 post-transplantation, the production of IL-10 as a characteristic sign of the Th2 response did significantly increase. Studies found that Th2 cytokines can be associated with downregulation of cell-mediated immune responses by antagonizing the effect of Th1 cytokines, thereby reducing GVHD. 40, 43 The expression of IL-17 in the supernatant of MLR with TLR4 1/1 mice cells was significantly higher than that of TLR4 2/2 mouse cell MLRs, which suggests that IL-17 may be an additional GVHD progression-promoting factor. IL-17 expression is related to a third subset of T cells and plays a critical role in the extracellular pathogen response, which may lead to inflammation and is also related to severe autoimmune diseases. 15 In summary, our results indicated that TLR4 gene deficiency keeps DCs in an immature state where they do not express high levels of CD80, CD86, CD40 or MHC-II, and their IL-12 secretion is blocked. This, in turn, leads to reduced CD4 1 T-cell maturation into Th1 phenotypes. With reduced T-cell proliferation and maturation, the severity of GVHD is lower in TLR4 2/2 -related BMT.
CONCLUSIONS
The LPS/TLR4 signal transduction pathway plays an important role in the immune response, which is mediated and primed by allogeneic T lymphocytes. Based upon this, we concluded that T cells from TLR4 2/2 -knockout mice cannot be effectively 1/1 or TLR4 2/2 as donor mice: the production of cytokines in sera derived from recipient BALB/c mice was analyzed on day 7 post-transplantation by ELISA. The levels of cytokines (IFN-c and IL-10) in the TLR4 2/2 group, as compared to the TLR4 1/1 donor mice group, were significantly increased. IL-2 levels in the TLR4 2/2 mice group were significantly lower than in TLR4
1/1 group (P,0.05), while IL-4 levels were not significantly different between both groups (Figure 7c ). Data shown are the mean6s.d. from at least three mice (*P,0.05, **P,0.01). BMT, bone marrow transplantation; ELISA, enzyme-linked immunosorbent assay; FACS, fluorescent activated cell sorting; IFN-c, interferon-c; TLR4, Toll-like receptor 4.
activated and do not proliferate under the stimulation of APCs. Therefore, TLR4
2/2 can lead to immune tolerance of allogeneic organ transplantation and thus significantly reduce the risk of developing GVHD.
